FindTrial
Sign In

A clinical study to observe the effects of 8.4% Sodium Bicarbonate impregnated steam inhalation on Covid-19 infected patients

A randomized open label parallel group trial to study the safety and efficacy of steam impregnated with 8.4 % Sodium Bicarbonate in patients with Covid-19 infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026535
Enrollment
60
Registered
2020-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Sodium Bicarbonate 8.4% Impregnated Steam Inhalation: 50 ml of 8.4% Sodium Bicarbonate through a naso-oral delivery apparatus attached to an electric steam generating apparatus. Frequen

Sponsors

Dr Bharat S Mody
Lead Sponsor
Myself Health Check Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Males and Females of age 18 years or more diagnosed with Covid-19 infection by RT-PCR test method and not on Invasive Ventilatory Support. Subject willing to give written consent (Volunteer Information Sheet and Informed Consent Form) prior to enrolment in the study. Subjects must have clinically acceptable results for all the screening parameters.

Exclusion criteria

Exclusion criteria: Males and Females not proven to have Covid-19 infection by a positive RT-PCR test result. Males and Females having proven Covid-19 infection by positive RT-PCR test result but on Invasive Ventilatory Support. Subject deemed uncooperative or noncompliant.

Design outcomes

Primary

MeasureTime frame
Reduction in laboratory values of the following inflammatory markers: ESR, CRP, Serum Ferritin, Serum Procalcitonin, Serum Lactate Dehydrogenase (LDH), and IL6 and improvement in clinical parameters. Reduction in laboratory values of the following coagulopathy marker: D Dimer Improvement in Clinical Parameters.Timepoint: 5 days—

Secondary

MeasureTime frame
N/ATimepoint: N/A—

Countries

India

Contacts

Public ContactDr Kshitij B Mody

Welcare Hospital

joints.mody@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026